SMC kicks off the new year by accepting five new medicines for NHS use
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Read More
Tag: Rozlytrek
Roche’s tumour-agnostic therapy Rozlytrek approved in EU
Therapy has been approved to treat advanced NTRK fusion-positive solid tumours
Read More
NICE backs Rozlytrek for subset of NSCLC patients
Rozlytrek is one of a new group of histology-independent cancer treatments designed to treat tumours regardless of where the primary tumour originates
Read More
New vaccine for Ebola among CHMP recommendations
The vaccine could be Janssen’s first to win EU approval
Read More
Rozlytrek bags FDA approval
For the indication of ROS1-positive, metastatic non-small cell lung cancer (NSCLC).
Read More
- Transgene completes randomisation in phase 2 trial of tg4050
- Bayer wins MHRA approval for Kerendia in heart failure
- Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb
- Kainova expands DT 7012 trial into Europe
- Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
